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OBJECTIVE—The G319S HNF1A variant is associated with an
increased risk of type 2 diabetes in the Canadian Oji-Cree
population. We hypothesized that the variant site at the 3 end of
exon 4 might inﬂuence splicing and characterized mRNA tran-
scripts to investigate the mutational mechanism underlying this
susceptibility to diabetes.
RESEARCH DESIGN AND METHODS—We established lym-
phoblastoid cell lines from a G319S homozygote and controls.
HNF1A transcripts were characterized in the cell lines and
pancreatic tissue by sequence analysis of RT-PCR products and
quantiﬁcation using real-time PCR. Susceptibility to mRNA sur-
veillance was investigated using cycloheximide.
RESULTS—Full-length G319S mRNA accounted for 24% of
mRNA transcripts in the homozygous G319S cell line. A novel
isoform lacking the terminal 12 bases of exon 4 was upregulated
(55% of mRNA transcripts) compared with control cell lines
(33%) and human pancreatic tissue (17%). Two abnormal tran-
scripts present only in the G319S cell line included premature
termination codons as a result of the inclusion of seven nucleo-
tides from intron 4 or the deletion of exon 8. Cycloheximide
treatment increased the levels of both transcripts.
CONCLUSIONS—The G319S variant results in the production
of two abnormal transcripts and an alteration in the relative
balance of normal splicing products. This is predicted to lead to
a reduction in total HNF1A transcript levels, but residual hepa-
tocyte nuclear factor-1 protein activity in G319S homozygotes
may still reach up to 66% of normal levels. A combination of
abnormal splicing and reduced activity of the G319S protein may
explain the diabetes susceptibility. Diabetes 57:1978–1982,
2008
T
he Oji-Cree are an isolated population from
North Central Canada who are among the most
diabetes-prone subpopulations in the world; al-
most 40% of adults (1) and a high proportion of
adolescents (2) have diabetes. Clinical heterogeneity in
the disease phenotype suggests that diabetes in the Oji-
Cree may have both genetic and environmental compo-
nents (2–4). The most common genetic susceptibility
determinant is a GA base substitution at nucleotide 955
(c.955GA) in the hepatocyte nuclear factor (HNF)1 ho-
meobox A (HNF1A) gene, rare mutations that cause
maturity-onset diabetes of the young (MODY) (5). This
variant is found only in the Oji-Cree and is predicted to
result in a glycine to serine substitution at codon 319
(p.Gly319Ser; G319S). Almost 40% of diabetic subjects
carry the G319S variant, with an odds ratio of 1.97 for
heterozygotes and 4.00 for G319S homozygotes compared
with subjects without the variant (6).
Oji-Cree subjects without the variant show the charac-
teristic features of type 2 diabetes with high levels of
obesity, high plasma insulin, and insulin resistance (2).
The diabetic phenotype of G319S carriers is more consis-
tent with a defect in insulin secretion, with an earlier onset
of diabetes, less obesity, and lower insulin levels than in
diabetic noncarriers (2). Although some of the insulin-
resistance features that have been reported in Oji-Cree
diabetic subjects may arise from their unique genetic
background, it is more likely that most of these features
arise from the concurrent obesity in this population (2).
The G319S variant is located within the proline-rich
domain II of the transactivation domain (7) but outside the
regions important for nuclear localization or maximum
transactivation capacity (8). In vitro transient transactiva-
tion studies demonstrated reduced transactivation activity
of the HNF-1 protein by 54% compared with the wild-type
protein. No dominant-negative effects or inﬂuences on
protein stability or DNA binding were observed (4). The
G319S missense variant results from a base substitution at
the most 3 nucleotide of exon 4. This base is located
within the conserved intron 4 splice donor site, and we
hypothesized that the c.955GA variant might affect splic-
ing. In this study, we determined the sequence and levels
of HNF1A mRNA transcripts expressed in Epstein Barr
virus (EBV)-transformed lymphoblastoid cells derived
from a G319S homozygote and two controls. We demon-
strate that the G319S variant leads to the production of
two abnormal transcripts and disrupts the normal balance
of HNF1A expression.
RESEARCH DESIGN AND METHODS
The G319S homozygous subject was diagnosed with diabetes at 13 years of
age. He was asymptomatic at presentation, with no history of polyuria,
polydypsia, or weight loss. He had no acanthosis nigricans, dyslipidemia,
hypertension, or evidence of nonalcoholic fatty liver disease. There was a
family history of diabetes affecting two maternal aunts, the maternal grand-
mother, the father, and two paternal uncles. Informed consent was obtained
from all participants. The study was approved by the Health Research Ethics
Board, University of Manitoba, and was carried out in accordance with the
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1978 DIABETES, VOL. 57, JULY 2008Declaration of Helsinki. Commercially available human pancreatic RNA was
obtained from a pool of ﬁve donors aged 24–77 years (Clontech, Oxford, U.K.).
EBV transformation. Cell lines were established from the G319S homozy-
gous subject and two unrelated control subjects by EBV transformation of
peripheral blood lymphocytes (ECACC, Porton Down, Salisbury, U.K.). Cell
lines were maintained in 1 RPMI-1640 (Gibco Life Technologies, Paisley,
U.K.), supplemented with 10% fetal calf serum (Gibco Life Technologies).
RNA extraction and reverse transcription. Total RNA was extracted from
1  10
6 lymphoblastoid cells using the Perfect RNA Mini RNA kit (Eppen-
dorf, Hamburg, Germany). Complementary DNA (cDNA) was synthesized
from 4.5 g total RNA using the Thermoscript RT-PCR system (Gibco Life
Technologies), with 50°C as the incubation temperature.
Characterization of HNF1A transcripts. HNF1A transcripts were ampli-
ﬁed in triplicate from G319S and control mRNAs as previously described (9).
Individual splice products were then isolated by bandstab PCR and sequenced
(10). To investigate the occurrence of variants in cis/trans, long-range PCR
was used with primers EX4FP, EX4FS, EX9RP, and EX9RS (Table 1).
Real-time PCR quantiﬁcation of G319S and normal transcripts. Ectopic
mRNA transcripts were ampliﬁed from lymphoblastoid cells using a single-
tube TaqMan approach on the ABI Prism 7900 platform (Applied Biosystems,
Warrington, U.K.). Primer and probe sequences are given in Table 1. Triplicate
single-round reactions were carried out for each cell line using 2 l cDNA.
PCR products were detected by the use of mutation-speciﬁc probes that were
identical except for the site of the mutation (Table 1), as previously described
(9,10). Final proﬁles were pooled from at least two separate reverse transcrip-
tions to ensure accuracy.
Relative quantiﬁcation of normal and mutant transcripts. Relative
quantiﬁcation of the two transcripts was carried out using the equation 2
Ct
described by Applied Biosystems (Foster City, CA) (11). The ubiquitously
expressed 	-2 microglobulin (2M) gene was selected as an endogenous
control. An assay for this gene (Assay Hs00187842) was purchased by
Assays-on-Demand from Applied Biosystems (Foster City, CA).
Inhibition of nonsense-mediated mRNA decay. To determine whether any
observed reductions in the amount of mutant transcripts were due to
nonsense-mediated mRNA decay (NMD), cell cultures were split and treated
for 4 h with either solvent alone (1% DMSO) or cycloheximide (100 g/ml in
DMSO) (Sigma, Poole, U.K.). Cells were then washed once with PBS (Gibco
Life Technologies) and harvested by centrifugation.
In silico prediction of splicing patterns and mRNA folding. The software
package used for splice site prediction is available from www.fruitﬂy.org, and
the secondary structure of mRNAs was predicted using MFOLD software
(http://www.bioinfo.rpi.edu/applications/mfold) (12,13).
RESULTS
Bioinformatic tools predicted a high score (0.99) for the
native splice donor site of intron 4, which was reduced
to 0.94 by the G319S variant. An alternative cryptic
splice site 12 bp 5 of the native splice donor site was
also indicated with a score of 0.94 in both normal and
G319S sequences.
Analysis of cDNA from the homozygous G319S subject
revealed four different sequences (Fig. 1A–D). Transcript 1
corresponds with the full-length HNF1A product including
the G319S substitution (Fig. 1A). Transcript 2 corresponds
with use of the alternative splice donor site and the
generation of an mRNA transcript lacking 12 base pairs at
the 3 end of exon 4, which includes nucleotide 955 (the
site of the G319S substitution) (Fig. 1B). These mRNAs
will result in the translation of an in-frame protein of either
631 or 627 amino acids, respectively. Transcript 3 shows a
small insertion of 7 bp of intron 4 immediately following
the G319S variant (Fig. 1C). This results from the use of a
further intron 4 splice donor site 3 of the native site. The
7 bp insertion disrupts the reading frame, and a premature
termination codon is introduced at codon 332 in exon 5.
The fourth transcript shows complete skipping of exon 8
in addition to the 7 bp insertion from intron 4 predicted to
result in premature termination at codon 332 (Fig. 1D).
Long-range PCR analysis conﬁrmed that the IVS4nt 
 7
insertion and the exon 8 deletion are present within the
same transcript (in cis).
The four mRNA transcripts identiﬁed in the G319S
homozygous cell line were quantiﬁed by real-time PCR
(Fig. 2A). The most abundant transcript was transcript 2,
which comprised 55% of HNF1A mRNA transcripts. This
transcript results from the use of a cryptic spice site 12 bp
proximal to the native splice donor site of intron 4. The
full-length G319S transcript (transcript 1) represented 24%
of total HNF1A expression, with transcripts 3 and 4 at 15
and 6%, respectively. The levels of transcripts 3 and 4 were
increased 1.6- and 1.7-fold, respectively, by the addition of
TABLE 1
Nested and real-time PCR probe and primer sequences
Probe/primer name Sequence Labels
EX4FP 5’ TGCGTGTCTACAACTGGTTTG 3’ None
EX9RP 5’ AGGGTGGTGGCCTGAGAT 3’ None
EX4FS 5’ TGGCCATGGACACGTACAG 3’ None
EX9RS 5’ GTGAAGCCCGGACTCACTG 3’ None
HNF1A-WT-F 5’ CCCTCTCCCCCAGTAAGGT 3’ None
HNF1A-WT-R 5’ AGGGTACTTCTGCAGTCTCACT 3’ None
HNF1A-WT-P 5’ CACGGTGTGCGCTATG 3’ 5’ 6-FAM, 3’-MGB
G319S-FL-F 5’ TGCCCTCTCCCCCAGTAAG 3’ None
G319S-FL-R 5’ AGGGTACTTCTGCAGTCTCACT 3’ None
G319S-FL-P 5’ TCCACAGTGTGCGCTATG 3’ 5’ 6-FAM, 3’-MGB
Ex412bpdel-F 5’ CCTCCACCTGCCCTCTC 3’ None
Ex412bpdel-R 5’ AGGGTACTTCTGCAGTCTCACT 3’ None
Ex412bpdel-P 5’ CCCCAGTGTGCGCTATG 3’ 5’ 6-FAM, 3’-MGB
IVS4ins7-F 5’ CTCCACCTGCCCTCTCC 3’ None
IVS4ins7-R 5’ TCGCAGGCTGTCCATAGC 3’ None
IVS4ins7-P 5’ ACCACTTACTGTGGACCTTA 3’ 5’ 6-FAM, 3’-MGB
Ex8del-F 5’ CCCCTTCATGGCCACCAT 3’ None
Ex8del-R 5’ GTGTGAAGCCCGGACTCA 3’ None
Ex8del-P 5’ CCCCACGGTCTTCACC 3’ 5’ 6-FAM, 3’-MGB
The sequences of nested PCR primers and oligonucleotides used in the real-time quantiﬁcation are given. The label 6-FAM refers to
6-ﬂuorosceine and MGB refers to the minor groove binding non-ﬂuorescent quencher. Forward primers are given by F sufﬁx, reverse primers
by R sufﬁx, and probes by P sufﬁx.
L.W. HARRIES AND ASSOCIATES
DIABETES, VOL. 57, JULY 2008 1979the translation blocker cycloheximide, which abolishes
the nonsense-mediated decay mRNA surveillance pathway
(14). Transcript 2 was also present in both normal cell
lines and in human pancreatic tissue (28, 38, and 17% of
total HNF1A expression, respectively), which suggests
that it is a normal splice variant and may not compromise
HNF-1 activity (Figs. 2B and C).
The c.955GA base substitution is predicted to alter
the secondary structure of the HNF1A pre-RNA (Fig. 3A
and B). When guanine is present at nucleotide 955, the
sequences ﬂanking the splice donor site of exon 4 are
held in a relatively open conformation, but when ade-
nine is substituted, they are incorporated into a double-
stranded region (Figs. 3C and D). These changes in
Exon 7 Exon 8 Exon 9
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ag gt ag gt
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FIG. 1. Schematic of G319S variant transcripts. The mRNA sequences of transcript 1 (A), transcript 2 (B), transcript 3 (C), and transcript 4 (D)
are given below. Lowercase letters in italics refer to the conserved splice sites present in the introns. The position of G319S at nt955 is marked
by an arrow. Cryptic splice sites are marked with stars. The junction sequences of the abnormal transcripts are provided. The sequence deriving
from the 5 exon are in normal type, and the sequence deriving from the 3 spliced exon are underlined and given in italics. Sequences derived
from introns are in lowercase. The position of the 12-bp deletion is given by a hatched box, and the position of the 7-bp insertion is given by a
black box. The position of the G319S variant on the sequence is marked in capitals where appropriate.
HNF1A G319S AND mRNA SPLICING
1980 DIABETES, VOL. 57, JULY 2008mRNA secondary structure predict a global change in
conformation, which may obscure binding sites for
splicing factors.
DISCUSSION
The HNF1A G319S variant may moderate diabetes suscep-
tibility through the disruption of normal mRNA splicing.
We detected two abnormal transcripts (transcripts 3 and
4) in the G319S cell line that result in premature termina-
tion codons. We also identiﬁed a novel isoform, transcript
2, that arises from the use of a cryptic splice donor site 12
bases upstream of the native intron 4 splice donor site.
This is the major HNF1A isoform (55%) in G319S lympho-
blastoid cells but was also present in normal control cell
lines and human pancreas at lower levels (33 and 17%,
respectively). The G319S variant does not completely
abolish the use of the native splice donor site, since
full-length G319S transcripts were also present (24% of
transcripts).
The identiﬁcation of an mRNA transcript lacking exon 8
was unexpected since this exon is located 4.6 kb down-
stream from the c.955GA substitution. Mutations located
close to one splice site causing deletion of remote exons
have been reported before (15), but they are rare. One
possible explanation may be that alterations in the confor-
mation of the nascent hnRNA (pre-mRNA) transcripts may
inﬂuence both splice site choice and the stability of the
resultant mRNA (16–18). The inclusion of sequences from
intron 4 may therefore disrupt the secondary structure of
the transcript and prevent binding of proteins to additional
splicing factors such as exon splicing enhancers. The
predicted changes in RNA secondary structure resulting
from the intron 4 insertion (Fig. 3B) are consistent with
this hypothesis.
This study has identiﬁed a novel HNF1A isoform (tran-
script 2) expressed in lymphoblastoid cell lines and adult
human pancreas. This isoform lacks the 3 terminal four
amino acid residues of exon 4 that are not located within
any of the regions required for maximal transactivation
capacity or nuclear localization (8). It seems unlikely that
this isoform would have reduced functional activity. Pre-
vious in vitro functional studies of full-length G319S
protein showed a reduction in HNF-1 activity by 54%
(4). This transcript represented 24% of total mRNA and is
estimated to account for 11% of active HNF-1 protein in
G319S homozygotes. This, together with the predicted 55%
activity attributable to transcript 2, suggests that G319S
homozygotes might retain up to 66% of HNF-1 activity.
The levels of active HNF-1 protein in a G319S heterozy-
gote are predicted to be intermediate between these and
normal levels.
The Oji-Cree diabetic phenotype associated with the
G319S variant is consistent with reduced insulin secretion
and is likely to be a consequence of reduced HNF-1
activity. Our results suggest that the residual level of
transactivation activity is greater than that observed in
HNF1A-MODY, where the mutational mechanism of hap-
loinsufﬁciency was conﬁrmed by the identiﬁcation of
heterozygous gene deletions (20–22). The reduction in
HNF-1 activity may result from a combination of NMD-
mediated reduction in mRNA levels due to the premature
termination codon–containing transcripts and the reduced
function of the full-length G319S protein. The aberrant
splicing resulting from the base substitution at the 3 end
of exon 4 moderates the diabetic phenotype through the
upregulation of a novel isoform that is predicted to have
normal transactivation activity.
We considered the possibility that other coding poly-































































FIG. 2. Real-time PCR quantiﬁcation of G319S and wild-type tran-
scripts in lymphoblastoid cells and normal human pancreas. Real-time
quantitative data for G319S and normal transcripts are given for
normal (A) homozygous G319S cells (B) and normal human pancreas
(C). The percentages given are calculated relative to -2 microglobulin
(B2M) expression. The X-axis refers to the transcript identity, and the
Y-axis refers to the percentage of total HNF1A expression represented
by each transcript. Error bars represent the upper and lower limits of
quantiﬁcation based on three independent measurements. Differences
in expression proﬁle were analyzed statistically by comparison of the
Ct values (i.e., the crossing point of the test transcript relative to the
endogenous control) for full-length and 12-bp deletion-bearing tran-
scripts in lymphoblastoid cells by Mann-Whitney U test analysis.
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DIABETES, VOL. 57, JULY 2008 1981affect splicing, but the HNF1A coding single nucleotide
polymorphisms A98V and I27L are not located close to
conserved splice sites or exonic splice enhancers. Our
study demonstrates that susceptibility to type 2 diabetes in
the Oji-Cree may be mediated in part by aberrant splicing,
highlighting the potential utility of mRNA analysis in the
investigation of disease susceptibility alleles.
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FIG. 3. Predicted secondary structure of G319S hnRNAs and mRNAs.
The predicted secondary structures of G319 prespliced hnRNA (A),
S319 prespliced hnRNAs (B), G319S full-length processed mRNA (C),
and G319S IVS4ins7 processed mRNA transcripts (D) are given. The
positions of residue 319 within the transcript are marked by stars.
Note the alteration of secondary structure apparent in C and D.
HNF1A G319S AND mRNA SPLICING
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